Marc Beer, the Founder of Numerous Biotechs

Marc Beer is currently serving as the Chief Executive Officer of Renovia Inc., a company Mr. Beer co-founded in order to be able to develop gender-specific products for females with maladies unique to them. But, as anyone in business or otherwise can tell you, in order to develop any products, there must be capital with which to pour into research and development programs. Therefore, Marc Beer sought out investors and found three, the Missouri-based Ascension Ventures, the New York-based Perspective Advisors, and the Longwood Fund. Marc Beer successfully raised a sum of $42 million from these three healthcare investors. The $42 million raised will be used not only in the research and development of four new diagnostic and therapeutic products but also to develop and test an improved version of Leva, Renovia’s premiere product. Learn more:

Renovia Inc. was founded with the goal of providing women across the globe with a better means of treating their common female malady, which are classified as pelvic floor disorders. One of the most common pelvic floor disorders prevalent in women is urinary incontinence, a female malady that affects 250 million women globally. In April 2018, Renovia successfully obtained the FDA’s approval for Leva. Renovia has as its mission is the provision of women with a better means to diagnose and treat their pelvic floor disorders, in addition to improving their overall quality of life.

Marc Beer is the perfect CEO for Renovia in that he possesses more than 25 years of experience in the development and commercialization of biotechnology, devices, pharmaceuticals, and diagnostics. Marc Beer holds a an undergraduate degree from the Miami University located in Ohio. Apart from being one of the co-founder of Renovia, Marc Beer has founded a number of other biotech companies, such as ViaCell, Good Start Genetics, Inc., and Minerva Neurosciences Inc. In April 2000, Marc Beer founded ViaCell, a biotech company whose specialty is in the area of collecting blood stem cells in umbilical cord as well as developing and preserving it, and served for a number of years as its Chief Executive Officer. Marc’s exceptional leadership at ViaCell led to the biotech going public in 2005.